Cmic Holdings Co., a prominent player in the pharmaceutical and biotechnology industry, is headquartered in Japan (JP) and operates extensively across Asia and beyond. Founded in 2006, the company has established itself as a leader in contract research and manufacturing services, catering to a diverse clientele in the life sciences sector. Cmic Holdings is renowned for its comprehensive range of services, including drug development, clinical trial management, and regulatory affairs. What sets them apart is their commitment to innovation and quality, ensuring that clients receive tailored solutions that meet stringent industry standards. With a strong market position, Cmic Holdings has achieved significant milestones, including strategic partnerships and expansions that enhance its service offerings.
How does Cmic Holdings Co's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Cmic Holdings Co's score of 34 is higher than 66% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Cmic Holdings Co., based in Japan, reported total carbon emissions of approximately 8,000,000 kg CO2e, comprising 1,000,000 kg CO2e from Scope 1 and 7,000,000 kg CO2e from Scope 2. This marks a consistent emission level compared to 2023, where the company also recorded 8,000,000 kg CO2e in total emissions, with the same breakdown across scopes. Looking back to 2022, Cmic Holdings Co. reported significantly higher emissions of about 44,000,000 kg CO2e, with 14,000,000 kg CO2e from Scope 1 and 29,000,000 kg CO2e from Scope 2. This indicates a substantial reduction in emissions over the past two years, showcasing the company's commitment to lowering its carbon footprint. Cmic Holdings Co. has committed to near-term climate targets, although it has not set a net-zero target as of now. The company is actively engaged in climate initiatives within the pharmaceuticals, biotechnology, and life sciences sector, reflecting its dedication to sustainability. The emissions data is self-reported and does not cascade from any parent organization, ensuring that the figures are directly attributable to Cmic Holdings Co. itself.
Access structured emissions data, company-specific emission factors, and source documents
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|
Scope 1 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
Scope 2 | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 | 0,000,000 |
Scope 3 | - | - | - | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cmic Holdings Co is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.